Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 51 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: galantamine HBr Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder

NCT00195845
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Galantamine, Placebos
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 1, 2026, 6:53 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Galantamine Executive Function in Parkinson's Disease

NCT00211588
View directory record Official record
Conditions
Parkinson's Disease
Interventions
galantamine
Drug
Lead sponsor
Memorial Hospital of Rhode Island
Other
Eligibility
60 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Oct 1, 2026, 6:53 AM EDT
Recruiting Phase 2Phase 3 Interventional

Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)

NCT07625332
View directory record Official record
Conditions
Spinal Cord Injury, Traumatic Spinal Cord Injury, Paraplegia and Tetraplegia, Metabolic Syndrome
Interventions
Galantamine Hydrobromide Extended Release
Drug
Lead sponsor
Northwell Health
Other
Eligibility
21 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
West Orange, New Jersey • Manhasset, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 1, 2026, 6:53 AM EDT
Terminated Phase 4 Interventional

Galantamine Augmentation of Escitalopram for Treatment of Depression

NCT00423969
View directory record Official record
Conditions
Depression
Interventions
Galantamine, Escitalopram
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 18, 2007 · Synced Oct 1, 2026, 6:53 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans

NCT04769206
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Galantamine, Placebo, TENS 7000
Drug · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 1, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder

NCT00181636
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Galantamine-CR
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2007 · Synced Oct 1, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder

NCT00741598
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Galantamine-ER, Galantamine placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 1, 2026, 6:53 AM EDT
Completed Not applicable Interventional Results available

Galantamine Effects on Cognitive Function in Abstinent Cocaine Users

NCT00606801
View directory record Official record
Conditions
Cocaine Abuse
Interventions
Galantamine, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 1, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

NCT00551161
View directory record Official record
Conditions
Alzheimer Disease
Interventions
memantine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 1, 2026, 6:53 AM EDT
Terminated Not applicable Interventional Results available

Comparative Research of Alzheimer's Disease Drugs

NCT01362686
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Donepezil, Galantamine, Rivastigmine
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Fishers, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 1, 2026, 6:53 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study

NCT03014323
View directory record Official record
Conditions
Insulin Sensitivity, Oxidative Stress
Interventions
Galantamine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 1, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Galantamine Effects on Cognitive Function in Marijuana Users

NCT00969696
View directory record Official record
Conditions
Memory
Interventions
Placebo, Galantamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 1, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse

NCT00809835
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Galantamine, Computer Assisted Cognitive Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Bridgeport, Connecticut • Stratford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 1, 2026, 6:53 AM EDT
Completed Phase 2Phase 3 Interventional

Galantamine for Cognitive Deficits in Schizophrenia

NCT00463879
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 12, 2007 · Synced Oct 1, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke

NCT00227994
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
Galantamine, Donepezil
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 1, 2026, 6:53 AM EDT
Completed Early Phase 1 Interventional Results available

Galantamine and CBT4CBT Pilot to Prevent Relapse.

NCT03547622
View directory record Official record
Conditions
Methadone or Buprenorphine Detoxoxification
Interventions
MAT taper with galantamine, MAT taper with placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 1, 2026, 6:53 AM EDT
Completed Not applicable Interventional Results available

A Study to Help People Quit Smoking.

NCT01880099
View directory record Official record
Conditions
Nicotine Dependence
Interventions
placebo, Galantamine 8mg, Galantamine 16mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 1, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Galantamine for Cognition in People With Schizophrenia

NCT00320736
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
galantamine
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2009 · Synced Oct 1, 2026, 6:53 AM EDT
Completed Not applicable Interventional

An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms

NCT00161044
View directory record Official record
Conditions
Chronic Schizophrenia
Interventions
Galantamine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 1, 2026, 6:53 AM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)

NCT01039194
View directory record Official record
Conditions
Alzheimer Disease
Interventions
galantamine, BMS-708163
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 1, 2026, 6:53 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Galantamine in the Treatment of Post-Traumatic Headache

NCT00219869
View directory record Official record
Conditions
Post-Traumatic Headache, Head Trauma,Closed, Retention Disorders,Cognitive
Interventions
Galantamine
Drug
Lead sponsor
Rapoport, Alan, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 22, 2005 · Synced Oct 1, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional

Cognitive REmediation After Trauma Exposure Trial = CREATE Trial

NCT01416948
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Methylphenidate Hydrochloride 20 mg, Placebo Capsule, Galantamine 12 mg
Drug
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
San Diego, California • Boston, Massachusetts • Manchester, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 1, 2026, 6:53 AM EDT
Completed Not applicable Interventional Results available

Cognitive Enhancement as a Target for Cocaine Pharmacotherapy

NCT01531153
View directory record Official record
Conditions
Addiction
Interventions
Galantamine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 1, 2026, 6:53 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

NCT07284290
View directory record Official record
Conditions
Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls
Interventions
Syn-One skin biopsy, Multi modal MRI, Assessment of dynamic EEG features over 48-hour periods across all study aims, Plasma biomarkers, Galantamine HBr extended-release 8mg capsules (8mg ER).
Procedure · Diagnostic Test · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
50 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 1, 2026, 6:53 AM EDT